BioHarvest Sciences Inc. (BHST) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported strong financial performance with a 25% YoY revenue increase, improved gross margins, and higher net income. Despite regulatory risks, the positive revenue growth and operational efficiency are significant positives. No guidance was provided, which is neutral, but the overall financial health suggests a positive outlook. The lack of a market cap limits precise prediction, but generally, these financial results would likely lead to a positive stock price movement.
Key Financial Performance
Revenue BioHarvest Sciences reported a revenue of $12.5 million for Q4 2025, representing a 25% increase year-over-year. This growth was attributed to the successful launch of new product lines and expansion into new markets.
Gross Margin The gross margin for Q4 2025 was 65%, up from 60% in the same quarter last year. The improvement was driven by operational efficiencies and cost reductions in production.
Net Income Net income for Q4 2025 was $2.3 million, compared to $1.8 million in Q4 2024, marking a 27.8% increase. This was due to higher revenues and improved cost management.
Operating Expenses Operating expenses for Q4 2025 were $5.2 million, up 10% year-over-year. The increase was primarily due to higher marketing and R&D expenditures to support new product launches.
Cash Flow from Operations Cash flow from operations was $3.5 million in Q4 2025, a 16.7% increase from $3 million in Q4 2024. This improvement was driven by higher profitability and better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges risks and uncertainties related to regulatory compliance as highlighted in their SEC filings. These could impact future results or events.
Forward-Looking Statements: Management's forward-looking statements are subject to risks and uncertainties, which may cause actual results to differ materially from projections.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: The transcript does not provide specific details on strategic initiatives.
Guidance and Outlook: The transcript does not provide specific details on guidance and outlook.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act BioHarvest
Anderson Canaccord
Canaccord Genuity
Capital Partners
Chairman Chief
Chairman President
Co Founder
Dichter Chief
Division Anderson
Division Hello
Division Hewitt
Division Sean
Dr Chairman
EDT Chief
End Instructions
Executive Chairman
Form risk
Founder Executive
Greetings Dr
Group LLC
Head Investor
Hello BioHarvest
Instructions Justin
Investor Relations
Justin Meiklem
LLC Research
Litigation Reform
McGowan ROTH
Meiklem Head
Officer Co
Officer Ilan
Officer projection
Research Division
event
BHST Transcript
BioHarvest Sciences Inc. (BHST) Q4 2025 Earnings Call Transcript
Positive4-1
The company reported strong financial performance with a 25% YoY revenue increase, improved gross margins, and higher net income. Despite regulatory risks, the positive revenue growth and operational efficiency are significant positives. No guidance was provided, which is neutral, but the overall financial health suggests a positive outlook. The lack of a market cap limits precise prediction, but generally, these financial results would likely lead to a positive stock price movement.
BioHarvest Sciences Inc. (BHST) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call highlights strong revenue growth, improved gross margins, and a strategic focus on expanding VINIA products and CDMO services. The Q&A section reveals positive sentiment towards new product launches and partnerships, despite some uncertainty in management's timeline clarity. The company's strategic initiatives and financial metrics indicate a positive outlook, leading to a positive sentiment rating.
BioHarvest Sciences Inc. (BHST) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call summary and Q&A reveal strong revenue growth, improved margins, and promising product launches, notably the VINIA 2X Chews and hydration product. The partnership with Tate & Lyle and significant CDMO pipeline add optimism. Despite increased operating expenses and net loss, the company manages tariff impacts well and plans further margin improvements. Analysts show positive sentiment towards product and channel expansions, boosting the outlook. These factors suggest a positive stock price movement, especially given the company's strategic focus on high-growth areas and market expansion.
BioHarvest Sciences Inc. (BHST) Q1 2025 Earnings Call Transcript
Positive5-15
The earnings call indicates strong revenue growth, improved gross margins, and promising future revenue expectations. Despite some operational risks and unclear management responses, the company's expansion into new product categories and CDMO services, along with AI integration, suggests a positive outlook. The lack of a shareholder return plan is a slight downside. Overall, the positive financial performance and strategic initiatives outweigh the concerns, leading to a positive sentiment.
BHST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
